FTSE 100 news / Companies and sectors / AstraZeneca / AstraZeneca signs AI drug discovery deal with insitro
AstraZeneca signs AI drug discovery deal with insitro
+5.7 positive
Many outlets report AstraZeneca's collaboration with insitro worth up to about $1.5bn for MASH and cardiomyopathy targets.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| AD HOC NEWS | 3 | +6.7 |
| Pharmaceutical Technology | 1 | +7.0 |
| EMJ | 1 | +6.7 |
| Contract Pharma | 1 | +6.7 |
| Quartz | 1 | +6.7 |
| BioXconomy | 1 | +6.7 |
| Dealroom | 1 | +6.7 |
| Biostock | 1 | +6.7 |
| Tech in Asia | 1 | +6.7 |
| GDNOnline | 1 | +6.7 |
| Medical Dialogues | 1 | +6.7 |
| Indian Pharma Post | 1 | +6.7 |
| lifesciencesweden.se | 1 | +6.7 |
| Voice of Healthcare | 1 | +6.3 |
| Analytics Insight | 1 | +6.3 |
| BioSpace | 1 | +5.8 |
| The Business Journals | 1 | +5.8 |
| BioWorld News | 1 | +5.7 |
| Pharmaceutical Executive | 1 | +5.5 |
| Yahoo Finance | 1 | +5.5 |
| Pulse 2.0 | 1 | +5.5 |
| AllSci | 1 | +5.5 |
| 富途牛牛 | 1 | +5.5 |
| WSJ | 1 | +5.3 |
| The Pharma Letter | 1 | +5.3 |
| Benzinga | 1 | +5.3 |
| Belaaz | 1 | +5.3 |
| Reuters | 1 | +5.0 |
| finchannel | 1 | +5.0 |
| Sharecast | 1 | +5.0 |
| MedWatch | 1 | +5.0 |
| Fox Business | 1 | +5.0 |
| Endpoints News | 1 | +5.0 |
| ForkLog | 1 | +5.0 |
| Stocktwits | 1 | +5.0 |
| Crypto Briefing | 1 | +5.0 |
| TipRanks | 1 | +5.0 |
| PharmTech.com | 1 | +4.7 |
| Scientist Live | 1 | +4.2 |
| Axios | 1 | +4.2 |
| STAT | 1 | +2.5 |
Day by day
Sunday 18 October 2026
AstraZeneca announced a new collaboration with insitro.
- +7.5 AstraZeneca announces new insitro collaboration - ad-hoc-news.de
New collaboration with insitro supports its R&D pipeline.
Saturday 17 October 2026
Outlets report AstraZeneca and insitro signed an AI drug discovery partnership worth up to $1.5bn for liver and heart disease.
- +7.0 AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership
Large AI-powered cardiometabolic partnership. - +6.7 AstraZeneca agrees $40m AI drug discovery deal with insitro
AI drug discovery deal agreed. - +6.7 AstraZeneca, insitro Sign AI Drug Discovery Deal
AI drug discovery deal with insitro. - +6.7 AstraZeneca partners with AI biotech insitro on liver, heart drugs
Partnership with AI biotech on liver and heart drugs. - +6.7 AZ and insitro ink AI collaboration to target MASH and cardiomyopathies
AI collaboration targeting MASH and cardiomyopathies. - +6.7 insitro and AstraZeneca strike up to $1.5B AI drug-discovery partnership for liver and heart disease
Up to $1.5B AI partnership for liver and heart disease. - +6.7 AstraZeneca invests in AI against fatty liver and heart muscle disease
Investment in AI for fatty liver and heart disease. - +6.7 AstraZeneca strikes $1.5b AI drug discovery deal with Insitro
AI drug discovery deal with insitro. - +6.7 Health: AstraZeneca strikes $40 million AI drug discovery deal with insitro
AI drug discovery deal with insitro. - +6.7 AstraZeneca Partners with Insitro in USD1.5 Billion AI Drug Discovery Deal
Billion-dollar AI drug discovery deal. - +6.7 AstraZeneca teams up with insitro to harness AI for next-generation disease treatments
AI partnership for next-generation treatments. - +6.7 AstraZeneca strikes 1.5 billion dollar AI drug discovery deal
AI drug discovery deal worth 1.5 billion dollars. - +6.7 AstraZeneca announces USD 1.46 billion insitro deal: AstraZeneca stock trades at EUR 148.70 - ad-hoc-news.de
insitro deal announced; stock price noted. - +6.3 AstraZeneca, insitro Sign $40M AI Drug Deal
AI drug deal signed with insitro. - +4.2 AstraZeneca collaborates to identify novel drug targets
Collaboration to identify novel drug targets.
Friday 16 October 2026
Many outlets report AstraZeneca's collaboration with insitro worth up to about $1.5bn for MASH and cardiomyopathy targets.
- +6.3 AstraZeneca and insitro Sign USD 1.5 Billion AI Drug Discovery Partnership
Large AI partnership worth up to $1.5bn. - +5.8 AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
Expands MASH and cardio work via AI partnership. - +5.8 AI startup Insitro nails deal worth up to $1.4 billion with pharma giant AstraZeneca
Deal worth up to $1.4bn with AI startup. - +5.8 AstraZeneca announces insitro collaboration: stock pre-market at EUR 148.70 - ad-hoc-news.de
Collaboration announcement with insitro, mildly positive. - +5.7 Insitro’s Virtual Human attracts $1.5B MASH deal with Astrazeneca
Virtual Human platform attracts $1.5bn MASH deal. - +5.5 AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
AI deal for MASH worth up to $1.5bn. - +5.5 AstraZeneca (LSE:AZN) Enters AI Drug Discovery Partnership In MASH And Cardiomyopathies
AI partnership in MASH and cardiomyopathies. - +5.5 AstraZeneca And insitro Enter AI Drug Discovery Collaboration Worth Up To Approximately $1.5 Billion
Collaboration worth up to about $1.5bn. - +5.5 Insitro signs USD 1.5b deal with AstraZeneca to hunt MASH and cardiomyopathy targets with AI
Deal targets MASH and cardiomyopathy using AI. - +5.5 AstraZeneca joins the "AI + pharmaceuticals" boom: partnering with Insitro to develop drugs for fatty liver and cardiac diseases, with a $1.86 billion deal.
Joins AI pharma boom with $1.86bn deal. - +5.3 AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
WSJ reports up to $1.5bn AI deal. - +5.3 AstraZeneca enters new strategic collaboration with insitro
New strategic collaboration announced. - +5.3 AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
Billion-dollar AI deal for heart and liver disease. - +5.3 AstraZeneca Bets on AI Drug Discovery in $1.5 Billion Potential Partnership With Insitro
Bets on AI in potential $1.5bn partnership. - +5.0 AstraZeneca strikes $40 million AI drug discovery deal with insitro
Reuters reports AI drug discovery deal. - +5.0 AstraZeneca signs $40 million AI drug-discovery agreement with insitro
AI drug-discovery agreement signed with insitro. - +5.0 AstraZeneca enters into strategic drug discovery deal with AI biotech Insitro
Strategic drug discovery deal with AI biotech. - +5.0 AstraZeneca signs AI drug discovery deal for heart and liver diseases
AI drug discovery deal for heart and liver. - +5.0 AstraZeneca, Insitro strike AI drug discovery deal
AI drug discovery deal reported. - +5.0 AstraZeneca does AI deal with insitro; inVIOs’ Phase 1 success in solid tumors
AI deal with insitro reported. - +5.0 AstraZeneca to Invest Up to $1.5 Billion in AI-Driven Drug Discovery
Invests up to $1.5bn in AI drug discovery. - +5.0 AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know
Investor-focused piece on the AI deal. - +5.0 AstraZeneca signs AI drug discovery deal with insitro worth up to $1.86 billion
AI deal reported, value up to $1.86bn. - +5.0 AstraZeneca enters drug discovery collab, licensing agreement with insitro
Collaboration and licensing agreement with insitro. - +4.7 MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
Explains rationale for choosing insitro's AI. - +4.2 Mubadala takes Clear Channel private, International Paper's bidders, and Astrazeneca's $1.5b deal
Deal mentioned in a roundup of deals. - +2.5 Pharmalittle: We're reading about former FDA head calling DOGE a 'disaster,' an AstraZeneca AI deal, and more
AI deal mentioned in a news roundup.